Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 25Neoplasms 3Neoplasm Metastasis 3Stomach Neoplasms 1Sarcoma 1Osteitis Deformans 1Neoplastic Cells, Circulating 1Invasive Breast Cancer 1Head and Neck Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER2 Positive Metastatic Breast Cancer 1Esophageal Neoplasms 1Carcinoma 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Radiosurgery 23Radiotherapy 20Temozolomide 17Lomustine 9Bevacizumab 8Surgical Procedures, Operative 7Procarbazine 6Vincristine 5Nivolumab 5Memantine 5Magnetic Resonance Spectroscopy 4Filgrastim 4Etoposide 4Cisplatin 4Carboplatin 4Specimen Handling 3Sodium Chloride 3Radiation 3Methylphenidate 3Mental Status and Dementia Tests 3Granulocyte Colony-Stimulating Factor 3Gefitinib 3Cyclophosphamide 3Corticotropin-Releasing Hormone 3Carmustine 3icotinib 2etoposide phosphate 2efaproxiral 2X-Rays 2Tranexamic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Brain Neoplasms × Lapatinib × Clear all
NCT00820222 2019-04-02

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Novartis

Phase 3 Completed
540 enrolled 18 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡